Motley Fool Asset Management LLC Boosts Position in Illumina, Inc. (NASDAQ:ILMN)

Motley Fool Asset Management LLC raised its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,314 shares of the life sciences company’s stock after purchasing an additional 266 shares during the quarter. Motley Fool Asset Management LLC’s holdings in Illumina were worth $601,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Annis Gardner Whiting Capital Advisors LLC purchased a new position in shares of Illumina in the third quarter worth approximately $30,000. VisionPoint Advisory Group LLC grew its position in shares of Illumina by 344.6% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after acquiring an additional 193 shares during the period. Wetzel Investment Advisors Inc. purchased a new stake in shares of Illumina in the 4th quarter worth $37,000. Gradient Investments LLC raised its holdings in Illumina by 375.0% in the 4th quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock worth $40,000 after purchasing an additional 225 shares during the period. Finally, North Star Investment Management Corp. lifted its position in Illumina by 183.0% during the fourth quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company’s stock valued at $42,000 after purchasing an additional 194 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Illumina news, CEO Jacob Thaysen bought 7,330 shares of the company’s stock in a transaction on Thursday, February 22nd. The stock was acquired at an average price of $135.29 per share, for a total transaction of $991,675.70. Following the completion of the transaction, the chief executive officer now directly owns 14,861 shares of the company’s stock, valued at $2,010,544.69. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.17% of the stock is currently owned by corporate insiders.

Illumina Price Performance

Shares of Illumina stock opened at $122.28 on Friday. The stock has a market cap of $19.47 billion, a price-to-earnings ratio of -16.66 and a beta of 1.19. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. The stock has a 50 day moving average price of $131.51 and a 200-day moving average price of $127.39. Illumina, Inc. has a one year low of $89.00 and a one year high of $213.91.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The company had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same period in the previous year, the firm earned $0.14 earnings per share. Illumina’s quarterly revenue was up 3.6% compared to the same quarter last year. Equities analysts expect that Illumina, Inc. will post 0.91 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have commented on ILMN shares. Barclays upped their price target on Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a research report on Wednesday, April 10th. Stephens reaffirmed an “overweight” rating and set a $170.00 price target on shares of Illumina in a report on Wednesday, April 10th. StockNews.com upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $253.00 target price on shares of Illumina in a report on Tuesday, April 9th. Finally, TD Cowen lowered Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price target for the company. in a research note on Thursday, January 4th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Illumina presently has an average rating of “Hold” and a consensus target price of $167.70.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.